On October 18th, Zhongxin Fluoride Materials (002915.SZ) stated on an investor interaction platform that the company's pharmaceutical intermediates can be used in the field of Contract Research Organization (CRO) pharmaceutical research and development. Pharmaceutical intermediates are important chemical raw materials in the drug synthesis process, playing a key role in the development of new drugs. Currently, the company has formed pharmaceutical intermediates represented by the 2,3,4,5-tetrafluorobenzene series, nanosulfathiazole carboxylic acid, and trifluoroacetic acid series, and has a provincial-level small and medium-sized enterprise technology center, a provincial-level enterprise research institute - Zhejiang Zhongxin Fluoride Chemicals and New Materials Research Institute, dedicated to the research and development of high-end fluorine-containing fine chemicals such as pharmaceutical intermediates, pesticide intermediates, new materials, and electronic chemicals.